You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
|
|---|---|
| Published in |
Journal of Translational Medicine, September 2013
|
| DOI | 10.1186/1479-5876-11-215 |
| Pubmed ID | |
| Authors |
Zhiqiang Guo, Dali Cheng, Zhijun Xia, Meng Luan, Liangliang Wu, Gang Wang, Shulan Zhang |
| Abstract |
T-cell immunoglobulin and mucin domain 3 (TIM-3) is known as a negative immune regulator and emerging data have implicated TIM-3 a pivotal role in suppressing antitumor immunity. The co-stimulatory receptor CD137 is transiently upregulated on T-cells following activation and increases their proliferation and survival when engaged. Although antagonistic anti-TIM-3 or agonistic anti-CD137 antibodies can promote the rejection of several murine tumors, some poorly immunogenic tumors were refractory to this treatment. In this study, we sought to evaluate whether combined TIM-3 blockade and CD137 activation would significantly improve the immunotherapy in the murine ID8 ovarian cancer model. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Netherlands | 1 | <1% |
| Unknown | 118 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 42 | 35% |
| Student > Ph. D. Student | 19 | 16% |
| Student > Master | 10 | 8% |
| Student > Bachelor | 9 | 8% |
| Other | 5 | 4% |
| Other | 15 | 13% |
| Unknown | 20 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 29 | 24% |
| Immunology and Microbiology | 20 | 17% |
| Medicine and Dentistry | 17 | 14% |
| Biochemistry, Genetics and Molecular Biology | 15 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Other | 10 | 8% |
| Unknown | 24 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2024.
All research outputs
#3,709,974
of 25,371,288 outputs
Outputs from Journal of Translational Medicine
#668
of 4,634 outputs
Outputs of similar age
#32,069
of 213,525 outputs
Outputs of similar age from Journal of Translational Medicine
#6
of 78 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,634 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,525 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.